EffRx has entered into an exclusive license agreement with Diurnal Group plc, for the registration and commercialization of Efmody® as treatment for congenital adrenal hyperplasia (CAH) in Switzerland. Under the terms of the agreement, EffRx has received the exclusive rights to register and commercialize Efmody® in Switzerland.

Efmody® is a modified-release preparation of hydrocortisone that has been specifically designed for the treatment of patients with CAH, a rare condition caused by a genetic deficiency of adrenal enzymes. According to our estimates, there are approximately 450 patients in Switzerland suffering from CAH.

EffRx intends to submit a Market Authorisation Application (MAA) to Swissmedic as treatment for adolescent and adult patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH) in Switzerland during the second half of 2022. The MAA submission to Swissmedic for Efmody® will be based on the European regulatory dossier and published clinical trial data, with EffRx expecting potential market launch in Switzerland in 2024.

Scroll to Top